STOCKHOLM – January 30, 2013. Dilaforette, a Karolinska Development portfolio
company, today announces that the company has approval from the regulatory
authority in India to start a Phase II study with sevuparin in patients with
moderate to severe malaria.
Dilaforette and its collaborator, The Mahidol Oxford Tropical Medicine Research
Unit (MORU), plan to enroll 50 patients in India, where severe malaria remains
an important problem. The primary objective of the study is to evaluate safety
along with several efficacy parameters. The study design has been discussed at a
pre-IND meeting with the US Food and Drug Administration (FDA). The first study
site is open for enrollment and the first patients are expected in connection
with the coming rain season. A separate clinical trial in uncomplicated
falciparum malaria is already on-going in Thailand since 2011.

"The initiation of the Phase II trial at the ISPAT General Hospital in Rourkela
in India constitutes a major step in the development of sevuparin for severe
malaria. We are proud of the continued support we are receiving from world
leading expertise in the field of malaria", says Pirkko Sulila Tamsen, CEO,
Dilaforette.

"I have continued high expectations on sevuparin which interferes with a pivotal
culprit in malaria pathophysiology; blockage of the smallest blood vessels in
vital organs. It can potentially help to reduce mortality in cases of severe
malaria where antimalarial treatment alone is not sufficient", says Prof Arjen
Dondorp, Coordinating Principal Investigator, Department Head and Deputy
Director of the MORU.

There are about 10 million severe falciparum malaria cases every year resulting
in close to one million deaths, mostly children, despite optimal antimalarial
treatment. Sevuparin is a potential new adjunctive treatment of severe malaria
that acts by preventing and reversing the infected cells' ability to block blood
vessels.

"We have high hopes that sevuparin will make a difference in the treatment of
severe malaria. We also appreciate that Dilaforette has access to world leading
clinical expertise”, says Torbjörn Bjerke, CEO, Karolinska Development.

For further information, please contact:
Pirkko Sulila Tamsen, CEO, Dilaforette AB
Phone: +46 (0)70 302 95 88, e-mail: pirkko.tamsen@dilaforette.se

Torbjörn Bjerke, CEO, Karolinska Development AB
Phone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke@karolinskadevelopment.com

TO THE EDITORS

About Dilaforette
Dilaforette is a Swedish drug development company developing sevuparin, a
heparin derivative with low anticoagulant activity for the treatment of severe
malaria and vaso-occlusive crisis in Sickle Cell Disease.

In severe malaria, microvascular obstruction is caused by sequestration of
parasitized red blood cells and adhesive forces between infected/uninfected red
cells. This constitutes the central feature in the pathogenesis and is a direct
cause of acidosis, coma and death.

Sickle Cell Disease is a genetic life shortening disorder where one main feature
is the vaso-occlusive crisis caused by sickle cell shaped red blood cells that
obstruct blood flow in capillaries, resulting in ischemia and severe pain. For
more information, please visit www.dilaforette.se.

About Mahidol - Oxford Tropical Medicine Research Unit (MORU)
The MORU, supported by the Wellcome Trust, was founded in 1979 as a research
collaboration between the Faculty of Tropical Medicine, Mahidol University and
the University of Oxford. The main research interests are the epidemiology,
diagnosis, pathophysiology and treatment of malaria and other tropical
infections.

About Karolinska Development
Karolinska Development aims to create value for patients, researchers, and
investors by developing innovations from world class science into products that
can be sold or out-licensed with high returns. The business model is to: SELECT
the most commercially attractive medical innovations; DEVELOP innovations to the
stage where the greatest return on investment can be achieved; and COMMERCIALIZE
the innovations through the sale of companies or out-licensing of products. An
exclusive deal flow agreement with Karolinska Institutet Innovations AB, along
with other cooperation agreements with leading Nordic universities, delivers a
continuous flow of innovations. Today, the portfolio consists of 34 projects, of
which 15 are in clinical development. For more information, please visit
www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be
required to disclose the information provided herein pursuant to the Securities
Markets Act.